Searched for
GSK PHARMA RESULTS
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Stocks in news: L&T, Tata Power, Dabur, Marico, Torrent PharmaShares of Torrent Pharmaceuticals are expected to remain in focus on Wednesday as the company's promoter could sell 2.9% stake worth Rs 3,0...
- Will PLI help Indian pharma gain market share at cost of MNCs?Indian pharmaceutical companies are becoming more aggressive and increasing their market share and capex. Companies such as Divis, Dr Reddy...
- Glaxosmithkline Pharma Q1 Results: Net profit rises 8% to Rs 116 crore"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth wit...
- GSK Pharma sheds 2% as Q3 profit drops, expenses riseTotal income in October-December 2021 stood at Rs 826.24 crore as compared with Rs 805.89 crore in the year-ago period, PTI reported.
- GSK Pharma Q3 results: Net profit jumps over two-folds to Rs 204 crThe company had reported a net profit of Rs 76.47 crore in the same period of the previous fiscal.
- GSK to boost spending power of pharma business post break-upGlaxoSmithKline will lay out plans to boost the spending power of its research-focused pharmaceuticals business at an investor day. GSK's s...
- Board Meetings Today: Vedanta, Bharti Airtel, Torrent Pharma, Delta Corp and GSK PharmaAstrazeneca Pharma, Dr Lal Pathlabs and Monnet Ispat are among a few companies which will announce their March quarter results on Monday.
- GSK's tuberculosis vaccine shows promising resultsThe new vaccine, known as M72/AS01E, was tested at 11 sites in Kenya, South Africa and Zambia in adults whose blood tests showed they had l...
- GSK to recall Ranitidine from India after regulator alertBritish drugmaker will suspend release, distribution and supply of the heartburn drug.
- GSK Pharma profit up 6.53% at Rs 102.85 cr in Jan-Mar quarterGlaxoSmithKline Pharmaceuticals today reported 6.53 per cent increase in standalone net profit at Rs 102.85 crore for the Jan-March quarter.
- Bulls on the rampage, tailwinds take FMCG, pharma to fresh highsSharp drop in crude prices, slowing rate of inflation and downward trend in the interest rate cycle have created strong tailwinds for consu...
- Competition Commission of India clears Novartis-GlaxoSmithKline pharma dealThe multi-layered deal involves UK-based GlaxoSmithKline acquiring Novartis's vaccine biz, while latter would purchase GSK's cancer drugs p...
- Pick-up in local market boosts pharma MNCsA pick-up in the local pharma market augurs well for MNCs which are still recovering from the adverse impact of drug price control on high-...
- GlaxoSmithKline seeks FIPB nod to hike stake in Indian armGlaxoSmithKline has approached the FIPB to hike stake in its domestic arm by buying 24.33 per cent for an estimated Rs 6,400 crore.
- Pharma industry hit by worst slowdown in the domestic market for the month of AugustThe Indian pharma industry, while being on a roll due to the higher export realisations due to the weaker rupee, has suffered badly in the ...
- Q3 Earnings Preview: US market to help pharma put up healthy numbersThe weakening of the rupee during a good part of the quarter to December will also help boost export realisations.
- Angel Broking is neutral on GSK PharmaAngel Broking is neutral on GSK Pharma as it expects the company’s operating margin to remain flat at 34.5% and net profit to grow at 5.1 p...
Load More
